Spyre Therapeutics, Inc. SYRE EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s EPS (basic)?
- Spyre Therapeutics, Inc. (SYRE) reported EPS (basic) of -$0.74 in Q1 2026.
- How has Spyre Therapeutics, Inc.'s EPS (basic) changed year-over-year?
- Spyre Therapeutics, Inc.'s EPS (basic) decreased by 23.3% year-over-year, from -$0.60 to -$0.74.
- What is the long-term trend for Spyre Therapeutics, Inc.'s EPS (basic)?
- Over 3 years (2021 to 2025), Spyre Therapeutics, Inc.'s EPS (basic) has grown at a -57.1% compound annual growth rate (CAGR), from -$25.02 to -$1.98.
- What does EPS (basic) mean?
- The portion of a company's profit allocated to each outstanding share of common stock.
- How do you interpret EPS (basic)?
- An increase in basic EPS indicates improved earnings per share, while a negative value reflects a loss per share, signaling the extent to which the company is consuming capital.
- How does EPS (basic) compare across companies?
- Investors compare this against peer biotech companies to gauge the relative impact of capital structure and operational performance on shareholder value.